» Articles » PMID: 7535594

CD40 Ligand Triggered Interleukin-6 Secretion in Multiple Myeloma

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1995 Apr 1
PMID 7535594
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have suggested that interleukin-6 (IL-6) may mediate growth of multiple myeloma (MM) in either an autocrine or paracrine growth mechanism. However, those molecules which can trigger IL-6 secretion either by tumor cells or non-MM marrow cells are not well characterized. In the present study, we have examined the expression and functional significance of CD40 on MM and plasma cell leukemia (PCL) cells and derived cell lines, as well as long-term bone marrow stromal cells (BMSCs) and derived cell lines. CD40 was expressed on the majority of MM cells (> 90%) and BMSCs (> 70%). Triggering via CD40 using NIH3T3 CD40 ligand transfectant (CD40LT) cells increased (> 30%) cell surface CD80, CD18, CD11a, CD11b, and CD11c expression on MM cell lines. Culture with either fresh or paraformaldehyde fixed NIH3T3 CD40LT cells upregulates IL-6 secretion in MM cells and MM-derived cell lines, as well as normal and MM bone marrow mononuclear cells (BMMCs), BMSCs, and BMSC lines; this effect can be specifically blocked by anti-CD40 monoclonal antibody (MoAb). BMMCs and BMSCs from patients with MM secreted significantly more IL-6 than those from healthy donors (n = 3, P < .001); moreover, after stimulation using CD40L, IL-6 secretion was fourfold greater (n = 3, P < .001) from MM BMMCs and BMSCs than from normal BMMCs and BMSCs. Myeloma (CD38+CD45RA-) cells and non-MM (CD38+CD45RA+, CD38-CD45RA+, and CD38-CD45RA-) BMMCs were separated by dual fluorescence cell sorting. The latter secreted fourfold more IL-6 than the former (n = 2, P < .001). Increased IL-6 secretion (up to 28-fold) and proliferation (Stimulation index 10) by CD38+CD45RA-MM cells was triggered by culture with NIH3T3 CD40LT cells. Finally, anti-CD40MoAb partially (30%) blocked tumor cell to BMSC adhesion-induced IL-6 secretion. These studies support the view that CD40L may trigger IL-6 secretion by both MM cells and BMSCs and that IL-6-mediated autocrine and paracrine growth mechanisms may be possible in MM.

Citing Articles

Human immune organoids to decode B cell response in healthy donors and patients with lymphoma.

Zhong Z, Quinones-Perez M, Dai Z, Juarez V, Bhatia E, Carlson C Nat Mater. 2024; 24(2):297-311.

PMID: 39506098 PMC: 11866935. DOI: 10.1038/s41563-024-02037-1.


BACH2-mediated CD28 and CD40LG axes contribute to pathogenesis and progression of T-cell lymphoblastic leukemia.

Feng M, Zhang B, Li G, Yang Y, Liu J, Zhang Z Cell Death Dis. 2024; 15(1):59.

PMID: 38233409 PMC: 10794190. DOI: 10.1038/s41419-024-06453-8.


Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation.

Kielbassa K, Haselager M, Bax D, van Driel B, Dubois J, Levin M Leukemia. 2023; 37(6):1268-1276.

PMID: 37100883 PMC: 10244160. DOI: 10.1038/s41375-023-01898-w.


Termination of CD40L co-stimulation promotes human B cell differentiation into antibody-secreting cells.

Marsman C, Verstegen N, Streutker M, Jorritsma T, Boon L, Ten Brinke A Eur J Immunol. 2022; 52(10):1662-1675.

PMID: 36073009 PMC: 9825913. DOI: 10.1002/eji.202249972.


Determining if T cell antigens are naturally processed and presented on HLA class I molecules.

Friedman J, Gunti S, Lee M, Bai K, Hinrichs C, Allen C BMC Immunol. 2022; 23(1):5.

PMID: 35148673 PMC: 8832792. DOI: 10.1186/s12865-022-00478-4.